SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MannKind Corporation and Certain Officers – MNKD

NEW YORK, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against MannKind Corporation (“MannKind” or the “Company”) (NASDAQ: MNKD ) and certain of its officers.   The class action, filed in United States District Court, Central District of California, and docketed under 16-cv-00581, is on behalf of a class consisting of all persons or entities who purchased MannKind securities between August 10, 2015 and January 5, 2016 inclusive (the “Class Period”).  This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). 

If you are a shareholder who purchased MannKind securities during the Class Period, you have until March 15, 2016 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com .   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

MannKind, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

The Complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) contrary to Defendants' assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza; and (2) as a result, Defendants' statements about MannKind's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times. 

On January 5, 2016, MannKind issued a press release entitled “MannKind Corporation Announces Termination of License and Collaboration Agreement with Sanofi.”

Also on January 5, 2016, Bloomberg reported that Sanofi spokesman, Jack Cox, said in an emailed statement that Sanofi terminated the agreement with MannKind due to continued low level of prescriptions “despite our [Sanofi’s] substantial efforts.”

StreetInsider.com reported that Sanofi spokesman, Jack Cox, further said in his January 5, 2016 emailed statement that prescription levels of Afrezza never even met “modest expectations.”

On this news, the Company’s stock fell $0.70 per share, or over 48%, to close at $0.75 per share on January 5, 2015, damaging investors.

On January 6, 2015, James Rufus Koren of the LA Times , wrote an article entitled “A rare stumble for biotech pioneer Alfred Mann.” In the article, endocrinologist and early backer of Afrezza, Dr. Alan Marcus, stated that Afrezza was unsuccessful because of the FDA-mandated lung tests. Particularly since endocrinologists do not typically perform those tests, Dr. Marcus said that doctors had “no hands-on training with either lung testing equipment or with the Afrezza inhalers themselves.”

On this news, the Company’s stock fell $0.02 per share, or approximately 2.67%, to close at $0.73 per share on January 6, 2015, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 0

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 26

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 467

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 48

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 51

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 244

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

EDF Renewables Partners with OPPD for Sustainable Energy Growth

Updated Category News Views 184

EDF Renewables and Omaha Public Power District Join Forces EDF Renewables North America has announced a significant partnership with Omaha Public Power District (OPPD) to enhance the future of renewable energy. Their collaboration centers around the Milligan 1 Wind project, contributing to a larger initiative aimed at delivering cleaner, reliable energy to communities...

Continue Reading
Seaport Therapeutics Welcomes Lauren White as CFO in Growth Strategy

Updated Category News Views 128

Seaport Therapeutics Appoints Lauren White as Chief Financial Officer Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical firm focused on developing innovative neuropsychiatric therapies, recently announced an important leadership change, naming Lauren White as their new Chief Financial Officer. With an impressive track record in biotech financial...

Continue Reading
Lyte Fiber Secures $58 Million to Enhance Broadband Access

Updated Category News Views 461

Lyte Fiber Secures Funding to Expand Broadband Connectivity Lyte Fiber, LLC, based in Houston, has been awarded nearly $58 million through the State’s Bringing Online Opportunities to Texas (BOOT) II Program. This significant funding initiative aims to connect more than 6,750 underserved homes and businesses, thereby supporting the goal of widening broadband access in...

Continue Reading
Chipotle Faces Challenges as Young Consumers Turn to Home Cooking

Updated Category News Views 233

Understanding Current Dining Trends and Chipotle's Position As inflation continues to affect the retail and restaurant sectors, many dining establishments are feeling the pinch, particularly as lower-income consumers scale back on discretionary spending. Chipotle Mexican Grill Inc. (NYSE: CMG) recently faced significant losses in its stock value, dropping 19% in a single...

Continue Reading
Leadership Changes Propel zerohash for Future Growth

Updated Category News Views 288

Leadership Appointments at Zerohash New York-based zerohash has made significant strides in the crypto and stablecoin sector by welcoming Aaron Karczmer and Danny Rosenthal to its Boards of Directors. Their wealth of experience in payments and regulatory frameworks will be instrumental as the company navigates its next growth phase. Bringing Expertise to the Board Aaron...

Continue Reading